default author photo

Victoria Michael

McGovern Medical School at UTHealth

6431 Fannin

MSB 2.106

Houston, TX 77070

SCHOLARLY PAPERS

1

DOWNLOADS

47

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Oral cyclophosphamide combined with bevacizumab in recurrent heavily pretreated ovarian cancer

Number of pages: 22 Posted: 06 Nov 2025
affiliation not provided to SSRN, McGovern Medical School at UTHealth, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, affiliation not provided to SSRN, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine and affiliation not provided to SSRN
Downloads 47 (1,170,409)

Abstract:

Loading...

Recurrent ovarian cancer, High-grade serous ovarian cancer (HGSOC), Platinum resistant ovarian cancer (PROC), Cyclophosphamide, Bevacizumab.